Caitlin Clark may be an all-star on the basketball court, but she couldn’t beat Eli Manning when it came to a game of Pop-A-Shot. On the latest episode of The Eli Manning Show, the former NFL ...

Teladoc and LifeMD are partnering with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients. The two telehealth companies said Thursday they’re working ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1. ...

Eli Manning’s still got it — even off the football field. The legendary Giants quarterback, 44, faced off against WNBA star Caitlin Clark in a recent round of Pop-A-Shot on “The Eli Manning ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

Additionally, Teladoc Health (TDOC) signed an agreement with Eli Lilly’s (LLY) LillyDirect pharmacy partner, Gifthealth, to help streamline access to the weight-loss drug Zepbound. Another stock ...

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin ...

Late-breaking results from Eli Lilly and Company (LLY) and Incyte (INCY) found adolescent patients with severe alopecia areata, AA, treated with once-daily, oral baricitinib 4 mg and 2 mg saw ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over ...